A Phase 1 Trial Utilizing TMI With Fludarabine-Melphalan in Patients With Hematologic Malignancies Undergoing Second Allo-SCT

In this single-center, phase 1, dose-escalating study, researchers evaluated the efficacy of combining IM-TMI with conditioning fluarabine and melphalan in a cohort of 21 patients with hematological malignancies who were actively undergoing second or greater allo-SCT. In testing doses of 6 Gy, 9 Gy, and 12 Gy of IM-TMI, researchers were able to conclude that 12 Gy of IM-TMI combined with fluarabine and melphalan is a practical treatment in this patient population.

Access the full article to read more here.